B7-H4

B7-H4 Overview

English NameV-set domain-containing T-cell activation inhibitor 1Approved Drugs0
Drugs in Clinical Trials11Target SynonymV-Set Domain-Containing T-Cell Activation Inhibitor 1,Immune costimulatory protein B7-H4,B7h.5,B7 homolog 4,T-cell costimulatory molecule B7x,V-Set Domain Containing T Cell Activation Inhibitor 1,B7X,B7 Family Member, H4,T Cell Costimulatory Molecule B7x,B7S1,B7 Superfamily Member 1,VCTN1,PRO1291,FLJ22418,B7H4,B7-H4,Protein B7S1
Highest Development StagePhase 3 Clinical
English NameV-set domain-containing T-cell activation inhibitor 1
Target SynonymV-Set Domain-Containing T-Cell Activation Inhibitor 1,Immune costimulatory protein B7-H4,B7h.5,B7 homolog 4,T-cell costimulatory molecule B7x,V-Set Domain Containing T Cell Activation Inhibitor 1,B7X,B7 Family Member, H4,T Cell Costimulatory Molecule B7x,B7S1,B7 Superfamily Member 1,VCTN1,PRO1291,FLJ22418,B7H4,B7-H4,Protein B7S1
Approved Drugs0
Drugs in Clinical Trials11
Highest Development StagePhase 3 Clinical

B7-H4 Product List

  • Product Category

    Protein (11)Cell (1)

  • Product Status

    Launched (12)

  • Species

    Human (5)Mouse (3)Cynomolgus / Rhesus macaque (2)Rat (1)Canine (1)

  • Tag

    His Tag (7)His Tag & Avi Tag (3)Fc Tag (1)- (1)

  • Conjugate

    Unconjugated (6)Biotin-labeled (4)Azide Labeled (1)- (1)

B7-H4 Background

V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.

B7-H4 Synonyms

B7-H4,VTCN1,B7S1,B7h.5

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Puxitatug SamrotecanAZD8205; AZD-8205Phase 3 ClinicalAstrazeneca PlcBiliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Neoplasm Metastasis; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
Mocertatug RezetecanHS-20089; GSK-5733584; GSK5733584Phase 3 ClinicalShanghai Hansoh Biomedical Co LtdBreast Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
ABL-103ABL-103Phase 2 ClinicalAbl Bio Inc, Handok IncSolid tumours
Details
MHB-009CMHB-009C; MHB009CPhase 2 ClinicalMinghui Pharmaceutical (Hangzhou) Co LtdSolid tumours
Details
GEN-1047GEN-1047Phase 2 ClinicalGenmab A/SEndometrial Neoplasms
Details
DB-1312BG-C9074; DB-1312Phase 1 ClinicalDuality Biologics (Suzhou) Co LtdSolid tumours
Details
LNCB-74LNCB-74; LNCB74; LCB41APhase 1 ClinicalLigaChem Biosciences Inc, Nextcure IncBiliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Neoplasms; Ovarian Neoplasms; Solid tumours
Details
XKH-002XKH-002; XKH002Phase 1 ClinicalBeijing Kanova Biomedical Technology Co Ltd, Zhejiang Kanova Biopharmaceutical Co LtdNeoplasms; Solid tumours
Details
Felmetatug vedotinSGN-B7H4V; PF-08046048; SGN-B-7H-4V; SGNB-7H4V; SGNB-7H-4VPhase 1 ClinicalSeagen IncBreast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
Emiltatug LedadotinXMT-1660Phase 1 ClinicalMersana Therapeutics IncAbdominal Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms
Details
HBM-7008HBM7008; HBM-7008; R-7008; CLN-418Phase 1 ClinicalHarbour BiomedSolid tumours
Details

Product Reviews

  • 1***12019-11-16
    5People Like
    We purchased total of 600ug of this biotin-labeled antigen for liquid phase panning and antibody screening of affinity maturation. This antigen has good stability, high quality, and high repeatability for each experiment. Using this antigen, we screened high-affinity antibodies against this target. And using this antigen for screening of affinity maturation, we obtained antibodies with 10-times increased affinity. I highly recommended this product.
  • Overview
  • Product List
  • Product Reviews
  • Clinical Drug Information